KTRA oversold! Price target and stop lossKintara Therapeutics, Inc. (KTRA) oversold on the daily!
Based on support and resistance we have:
Price target: 2.60usd
Stop loss: 0.58usd
0%
0%
0%
0%
0%
About Kintara Therapeutics, Inc
Sector
Health Technology
Industry
Biotechnology
CEO
Robert E. Hoffman
Website
kintara.com
Headquarters
San Diego
Employees
20
Founded
2009
ISIN
US49720K2006
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
$KTRA price holding on strong support$KTRA price is holding on strong support. Waiting to see for a bounce
KTRA Bullish SetupShort term MAs are crossing the longer term MAs and the MACD is rising. I like yesterday's candle retesting the 0 fib level m testing the .38 level and closing above the .23 fib level.
Looking for a break of 1.76 to enter for a swing trade.
target: 1.92 in the short term.
KTRA 2x Phase two drugs data due soon.100m shelf popped out of the blue, now in effect. Phase two data is due and looks to be positive. Cap is under 60m. Seems very undervalued here. The shelf is strange because the CEO has stated that they had enough cash to get through Q4/21, so why the offering now?
Technical + Potential Catalyst. Low risk high rewardBroke out of a trend line and retested 1.30, looks to be heading towards 1.80 based on the sideways pattern. If it breaks out of sideways pattern there may be more upside.
Stop loss can be somewhere below the sideways pattern.
Kintara will be presenting in H.C. Wainwright Bioconnect 2021 Virtual Co
Kintara Therapeutics, Inc. On Breakout Alert Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headqu
See all ideas
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
